FDA 483 - Akeso Biopharma Co., Ltd. - March 04, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Akeso Biopharma, Co., Ltd. in Zhongshan, China, was cited for significant deficiencies during an FDA inspection of its drug substance and drug product manufacturing. The firm's visual inspection program, laboratory controls, and quality unit oversight were found to be inadequate. Additionally, issues were identified with procedures for preventing microbiological contamination, the design and maintenance of facilities and equipment, and non-conformance to submitted information regarding reference standard testing.
ID · 336122fa-825e-4aa9-b501-95130811edba